GlassScriptPhysician profile
Jared T Simmons
NPI 1093164667
$2,667.88
in general payments reported to CMS, 2019-2025
23 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $71.84 · 2023: $258 · 2024: $869 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.28 |
| Education | $147.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $458.56 | 2021-2025 | |
| Abbvie INC. | $451.02 | 2023-2025 | |
| Incyte Corporation | $290.42 | 2023-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $270.29 | 2021-2025 | |
| Pfizer INC. | $224.09 | 2021-2025 | |
| Leo Pharma INC. | $195.97 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $114.72 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $101.46 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $94.45 | 2023-2025 | Dupixent, Libtayo |
| Organon LLC | $57.04 | 2025 | Vtama |
| Botanix Sb INC | $47.35 | 2025 | Sofdra |
| Genzyme Corporation | $45.15 | 2021-2024 | |
| Verrica Pharmaceuticals INC. | $44.69 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.79 | 2024-2025 | Spevigo |
| Novartis Pharmaceuticals Corporation | $32.57 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $32.35 | 2025 | Aklief, Nemluvio |
| Journey Medical Corporation | $31.66 | 2023 | |
| Lnhc, INC | $24.63 | 2025 | Zelsuvmi |
| E.R. Squibb & Sons, L.L.C. | $24.55 | 2024 | Sotyktu |
| Amgen INC. | $22.90 | 2024 | Otezla |
| Organogenesis INC. | $21.76 | 2025 | Via Matrix |
| Almirall LLC | $20.77 | 2025 | Klisyri |
| Paratek Pharmaceuticals, INC. | $19.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.